Christine Biaggi Rudolf
Papers
1
Total Citations
32
H-Index
1
About
Dr. Christine Biaggi Rudolf is a leading clinical oncologist and researcher specializing in genitourinary malignancies, with a particular focus on muscle-invasive urothelial carcinoma (MIUC). Her work centers on optimizing perioperative treatment strategies to improve outcomes for patients with bladder cancer. Dr. Rudolf’s most notable contribution is her pioneering investigation of chemoimmunotherapy combinations in the neoadjuvant setting. She is the lead author of a landmark single-arm phase II trial (SAKK 06/17) exploring the integration of the PD-L1 inhibitor durvalumab with standard cisplatin/gemcitabine chemotherapy prior to surgery for operable MIUC. The preplanned interim analysis of this study, published in 2020, has garnered significant attention with 32 citations, highlighting its impact on the field. This work is critical as it addresses the high relapse rates seen with chemotherapy alone, testing whether adding immunotherapy can enhance pathologic complete response rates and long-term survival. By evaluating this novel triplet regimen, Dr. Rudolf is at the forefront of efforts to translate the promise of immune checkpoint inhibitors from the advanced disease setting into curative-intent treatment, potentially reshaping the standard of care for patients with this aggressive cancer.
Research Focus
Key Achievements
Top Papers
- 1